不同GLP-1受体激动剂对2型糖尿病患者肾脏结局的比较
本研究采用目标试验模拟框架,基于OptumLabs和Medicare理赔数据,纳入2019至2021年新处方GLP-1受体激动剂的成人2型糖尿病及中危心血管风险患者,比较度拉糖肽、艾塞那肽、利拉鲁肽和司美格鲁肽对肾脏结局的影响。结果显示主要肾脏复合结局无差异,但司美格鲁肽较度拉糖肽和艾塞那肽分别降低次要肾脏复合结局风险8%和12%,并较度拉糖肽降低死亡风险。
要点
- 四种GLP-1受体激动剂对主要肾脏复合结局无显著差异。
- 司美格鲁肽较度拉糖肽和艾塞那肽降低次要肾脏复合结局风险。
- 司美格鲁肽较度拉糖肽降低全因死亡风险。
核心结论
- 不同GLP-1受体激动剂对主要肾脏复合结局无差异,但司美格鲁肽与较低的次要肾脏复合结局和死亡风险相关。
研究设计与样本
- 回顾性观察性研究,采用目标试验模拟框架,使用OptumLabs数据仓库和Medicare按服务收费理赔数据。
- 纳入≥21岁、中危心血管风险、2019年1月1日至2021年12月31日新处方GLP-1受体激动剂的2型糖尿病成人。
主要发现
- 度拉糖肽、艾塞那肽、利拉鲁肽和司美格鲁肽对主要肾脏复合结局无差异。
- 与度拉糖肽相比,司美格鲁肽降低次要肾脏复合结局风险8%(HR 0.92,95%CI 0.87-0.97)。
- 与艾塞那肽相比,司美格鲁肽降低次要肾脏复合结局风险12%(HR 0.88,95%CI 0.79-0.99)。
- 与度拉糖肽相比,司美格鲁肽降低死亡风险(HR 0.81,95%CI 0.70-0.93)。
临床怎么用
- 在2型糖尿病和中危心血管风险患者中,司美格鲁肽可能优于其他GLP-1受体激动剂以延缓或预防慢性肾脏病。
局限性
- 可能存在残余混杂。
- 缺乏糖化血红蛋白和体重数据。
- GLP-1受体激动剂处方指征不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Glucagon-like peptide 1 (GLP-1) receptor agonist treatment is associated with a lower risk for incident chronic kidney disease (CKD) and death relative to treatment with a dipeptidyl peptidase 4 inhibitor or sulfonylurea. This study examined within class effects of GLP-1 receptor agonists on kidney outcomes in type 2 diabetes mellitus (T2DM) and moderate cardiovascular risk. STUDY DESIGN: Retrospective observational study using the target trial emulation framework. SETTING & PARTICIPANTS: This study used claims data from OptumLabs Data Warehouse and 100% sample of Medicare fee-for-service claims. Participants were adults ≥21 years of age, at moderate cardiovascular risk, who filled a new prescription for a GLP-1 receptor agonist between January 1, 2019 and December 31, 2021. EXPOSURE: GLP-1 receptor agonists dulaglutide, exenatide, liraglutide, or semaglutide. OUTCOME: A primary kidney composite outcome inclusive of incident diagnosis codes for CKD stages 3-4 and kidney failure (inclusive of CKD stage 5 and kidney replacement therapy). A secondary kidney composite outcome included the elements of the primary composite outcome plus death from any cause. Components of the kidney composite outcomes were also evaluated independently. ANALYTICAL APPROACH: Random treatment assignment was emulated using inverse probability of treatment weighting (IPTW) with propensity scores estimated using the SuperLearner ensemble method. Primary analyses were time-to-event models under the intention-to-treat framework using cause-specific IPTW Cox proportional hazards models. RESULTS: There was no difference among dulaglutide, exenatide, liraglutide, and semaglutide with respect to the primary outcome. When compared to dulaglutide and exenatide, semaglutide was associated with a reduced risk for the secondary kidney composite outcome by 8% (HR, 0.92 [95% CI, 0.87-0.97]) and 12% (HR, 0.88 [95% CI, 0.79-0.99]), respectively. Compared to dulaglutide, semaglutide was also associated with reduced risk of death (HR, 0.81 [95% CI, 0.70-0.93]). LIMITATIONS: Potential for residual confounding, lack of hemoglobin A1c and weight data, and uncertainty about the indication for GLP-1 receptor agonist prescriptions. CONCLUSIONS: No differences were observed among different GLP-1 receptor agonists for the primary outcome, but semaglutide initiation was associated with a lower risk of the secondary kidney composite outcome and of death. PLAIN-LANGUAGE SUMMARY: Chronic kidney disease (CKD) is a common complication of diabetes that increases the risk for poor health outcomes. Glucagon-like peptide-1 (GLP-1) receptor agonists were found to improve kidney outcomes in people with type 2 diabetes mellitus (T2DM) and moderate cardiovascular risk when compared with dipeptidyl peptidase-4 inhibitors and sulfonylureas. Although there has been no head-to-head comparison of individual GLP-1 receptor agonists, randomized controlled trials have suggested that there may be variation among members of this drug class on kidney disease outcomes. In this study, we tested whether there were differences in kidney outcomes when comparing individual GLP-1 receptor agonist medications. We found that semaglutide compared favorably to other drugs in the class and may represent the preferred GLP-1 receptor agonist for delaying or preventing CKD in this population.
引用
- Neumiller JJ, Deng Y, Swarna KS, et al. Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes. Am J Kidney Dis. 2026. PMID: 42302979. doi:10.1053/j.ajkd.2026.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。